Puma Biotechnology Inc Forecasted to Earn Q1 2018 Earnings of ($1.87) Per Share (PBYI)

Puma Biotechnology Inc (NASDAQ:PBYI) – Stock analysts at Leerink Swann issued their Q1 2018 earnings estimates for shares of Puma Biotechnology in a research note issued on Friday. Leerink Swann analyst M. Schmidt anticipates that the biopharmaceutical company will earn ($1.87) per share for the quarter. Leerink Swann has a “Outperform” rating and a $140.00 price target on the stock. Leerink Swann also issued estimates for Puma Biotechnology’s Q2 2018 earnings at ($1.55) EPS, Q3 2018 earnings at ($1.21) EPS and Q4 2018 earnings at ($0.90) EPS.

Other research analysts also recently issued research reports about the stock. Royal Bank of Canada dropped their target price on shares of Puma Biotechnology from $108.00 to $92.00 and set a “sector perform” rating for the company in a report on Friday, November 10th. They noted that the move was a valuation call. Credit Suisse Group reaffirmed an “outperform” rating and issued a $136.00 target price on shares of Puma Biotechnology in a report on Wednesday, September 27th. JPMorgan Chase & Co. reaffirmed a “buy” rating and issued a $131.00 target price on shares of Puma Biotechnology in a report on Wednesday, October 4th. Citigroup reaffirmed a “buy” rating and issued a $164.00 target price on shares of Puma Biotechnology in a report on Wednesday, January 3rd. Finally, ValuEngine downgraded shares of Puma Biotechnology from a “hold” rating to a “sell” rating in a report on Wednesday, January 3rd. Two investment analysts have rated the stock with a sell rating, one has issued a hold rating and nine have issued a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus price target of $130.67.

Shares of Puma Biotechnology (NASDAQ:PBYI) traded up $1.25 during trading on Monday, reaching $93.80. 515,400 shares of the company traded hands, compared to its average volume of 569,133. The company has a market cap of $3,520.00, a P/E ratio of -11.45 and a beta of 0.72. Puma Biotechnology has a one year low of $28.35 and a one year high of $136.90.

Puma Biotechnology (NASDAQ:PBYI) last issued its earnings results on Thursday, November 9th. The biopharmaceutical company reported ($2.07) earnings per share for the quarter, topping the consensus estimate of ($2.50) by $0.43. The firm had revenue of $6.10 million during the quarter, compared to the consensus estimate of $3.78 million. During the same period in the prior year, the company posted ($1.11) EPS.

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Ameritas Investment Partners Inc. boosted its holdings in shares of Puma Biotechnology by 5.9% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 2,522 shares of the biopharmaceutical company’s stock valued at $220,000 after purchasing an additional 140 shares during the last quarter. Rhumbline Advisers lifted its holdings in shares of Puma Biotechnology by 0.8% in the 2nd quarter. Rhumbline Advisers now owns 33,733 shares of the biopharmaceutical company’s stock valued at $2,948,000 after acquiring an additional 271 shares during the last quarter. The Manufacturers Life Insurance Company lifted its holdings in shares of Puma Biotechnology by 2.0% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 22,299 shares of the biopharmaceutical company’s stock valued at $1,950,000 after acquiring an additional 437 shares during the last quarter. California Public Employees Retirement System lifted its holdings in shares of Puma Biotechnology by 0.7% in the 3rd quarter. California Public Employees Retirement System now owns 108,000 shares of the biopharmaceutical company’s stock valued at $12,933,000 after acquiring an additional 800 shares during the last quarter. Finally, Parametric Portfolio Associates LLC lifted its holdings in shares of Puma Biotechnology by 13.5% in the 2nd quarter. Parametric Portfolio Associates LLC now owns 7,844 shares of the biopharmaceutical company’s stock valued at $686,000 after acquiring an additional 936 shares during the last quarter. 96.00% of the stock is owned by institutional investors and hedge funds.

In other Puma Biotechnology news, insider Charles R. Eyler sold 1,322 shares of the stock in a transaction dated Friday, December 1st. The shares were sold at an average price of $105.46, for a total transaction of $139,418.12. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 21.10% of the stock is owned by corporate insiders.

WARNING: This news story was first reported by Markets Daily and is the property of of Markets Daily. If you are reading this news story on another site, it was illegally copied and reposted in violation of US and international trademark & copyright laws. The correct version of this news story can be viewed at https://www.themarketsdaily.com/2018/01/10/puma-biotechnology-inc-forecasted-to-earn-q1-2018-earnings-of-1-87-per-share-pbyi.html.

Puma Biotechnology Company Profile

Puma Biotechnology, Inc is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing the development and commercialization rights to over three drug candidates, including PB272 (neratinib (oral)), PB272 (neratinib (intravenous)) and PB357.

Receive News & Ratings for Puma Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Puma Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply